GSK to cut up to 1,217 jobs in Belgium as part of restructuring plan

GSK announced plans on October 14, 2026, to potentially eliminate up to 1,217 jobs in Belgium as part of its 'Accelerate Growth' restructuring initiative. Launched by CEO Luke Miels in July 2026, the three-year program targets £1.9 billion in annual savings by 2029 to cushion an impending patent cliff for HIV drug dolutegravir. Cuts will span R&D, manufacturing, and support at sites in Rixensart, Wavre, and Gembloux, though GSK will maintain university partnerships and core vaccine production in Belgium.

Belgian job cuts and affected sites

• ▪The proposed GSK job cuts in Belgium would affect workers at sites in Rixensart, Wavre, and Gembloux out of a total Belgian workforce exceeding 8,000 employees
• ▪GSK announced on October 14, 2026 that it could cut up to 1,217 jobs across its Belgian operations as part of a proposed organizational restructuring

Global Accelerate Growth restructuring program

• ▪GSK's Accelerate Growth program aims to generate £1.9 billion ($2.5 billion) in annual savings by 2029 to offset an upcoming patent expiration for HIV drug dolutegravir
• ▪GSK plans to achieve global restructuring savings across its 66,800-person workforce by simplifying R&D, manufacturing, and support functions through increased digital tools and automation
• ▪The proposed Belgian workforce reductions are part of GSK's global Accelerate Growth restructuring program launched by Chief Executive Officer Luke Miels in July 2026

Belgian supply chain and manufacturing adjustments

• ▪GSK stated that its proposed job reductions in Belgium will not include factory workers at its manufacturing sites
• ▪GSK is adjusting its Belgian supply chain and manufacturing operations to address over-capacity and align production with changing global demand for established vaccines

Belgian R&D focus and reallocation

• ▪GSK plans to concentrate its Belgian R&D resources on high-priority projects, including GSK's mRNA influenza vaccine candidate
• ▪GSK is reducing Belgian R&D roles as part of a global effort to reallocate capital and resources toward GSK's late-stage development pipeline